Huaier Granule for Prevention of Recurrence and Metastasis of Stage II and III Non-small Cell Lung Cancer (NSCLC)

• Status: Terminated
• Trial end date: 2017-11-23
• Target enrollment: 0
• Participant gender: All

Summary

This study including two parts，one part is a randomized clinical trial design，another part is a registration study.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Qidong Gaitianli Medicines Co., Ltd

Criteria

Inclusion Criteria:

• Patients with complete resection who are at TNM (primary tumor, regional nodes, metastasis) stage II-Ⅲa, postoperative pathology confirmed for non-small cell lung cancer;

• Has completed four cycle standard solution of adjuvant chemotherapy, or refused to accept the postoperative adjuvant chemotherapy;

• Patients between 18 and 70 years old, no gender restriction;

• Eastern Cooperative Oncology Group (ECOG) PS of two or less;

• Before the start of the study, patient fully understands the study and is willing to sign the informed consent form;

Exclusion Criteria:

• Receiving adjuvant chemotherapy patients started greater than 24 weeks from surgical resection;

• Refused adjuvant chemotherapy patients started greater than 8 weeks from surgical resection;

• Suspected malignant pleural effusion;

• There is no clear pathological diagnosis;

• Combined with other cancer;

• Patient have a positive surgical margin;

• Accept other treatment for lung cancer of postoperative；

• Combined with severe idiopathic disease of liver, kidney and hematopoietic system;

• Combined psychosis or AIDS;

• Allergy to the test drug;

• Pregnant or lactating women;

• Participation in any other clinical trial within three months;

• Conditions that are considered not suitable for this study investigators.